Earnings are out (-$0.86 vs -$0.64 est.) & launch of JUXTAPID is imminent
They are ramping up the sales force and related support for the imminent launch of JUXTAPID.
Loss was higher (-$0.86/share) than street estimates (-$0.64/share) , but were directly in line with an accelerated launch. Most projections had the ramp up hitting next quarter.
Also, management is smart to keep downplaying the number of potential patients for JUXTAPID, that way when revenues come in early that show a large percentage capture, it looks good. Then it will look REALLY good when the # of patients actually buying the drug far surpasses the ultra-conservative numbers the company announced.
The company apparently has 250-300 identified, named patients, who are already ready and qualified for the drug, which is substantially different from the total patient population, but still legally supports the company's claim for just 250-300 patients.